Astigi: manufacturing backlog, delivery phasing and strategic-customer advances
Astigi's year-end 2025 manufacturing backlog is real signed business, but it is not equally near dated: 56.5% is scheduled for 2026, another 32.1% for 2027, and some of the deferrals are now backed by customer advances and interest. That improves the funding quality of the backlog, not the proof of fast revenue and profit conversion.
What This Follow-up Is Testing
The main article already showed that Astigi's manufacturing arm became material in 2025, but that the second half weakened the read. This follow-up isolates the question that decides how much weight that backlog really deserves: how much of it is close to revenue, how much is already supported by advances or interest, and how much has simply moved to the right on the delivery calendar.
There is good news here, and there is a limit to the good news. The good news is that the development-and-manufacturing backlog at year-end 2025 is not a soft pipeline. It reflects orders actually received. It also edged up to NIS 76.4 million from NIS 74.8 million a year earlier, and to NIS 77.8 million near the report date. The limit is timing: only NIS 43.2 million is expected for 2026, another NIS 24.5 million for 2027, and NIS 8.7 million only from 2028 onward. In other words, the backlog is real, but it is less near term than the headline backlog number suggests.
That is where the two strategic customer contracts matter. Neither one was cancelled. Both were rephased. But they are not the same economic story: one pushes part of the delivery schedule into the first half of 2026 and even gets a follow-on order, while the other effectively becomes a longer program through 2030, with additional customer advances and prime-rate interest on about $6 million deferred from the original end-2025 timing. That improves the funding quality of the delay. It does not remove the delay from revenue recognition.
Two Rephasings, Not One Economic Read
| Contract thread | What changed | Cash protection layer | What it really means |
|---|---|---|---|
| The May 2022 agreement, about $9.1 million | In May 2025 the parties agreed that half the systems would be supplied by end-2025 and the rest by the first half of 2026 | This note does not disclose a dedicated advance or interest term for that amendment | This looks like a relatively short delay, and not the end of the commercial relationship, because Astigi also signed a $5 million follow-on agreement for identical systems |
| The June 2022 agreement, as updated | In October 2025 supply was extended through 2030. About 85% of the order, about $14 million, is now due by end-2027, with a small additional portion in 2028 to 2029 and an immaterial remainder by 2030 | $1.7 million had already been paid as advances, another $2.6 million was due in the first quarter of 2026, for $4.3 million in total. About $6 million deferred from the original end-2025 schedule, net of advances, bears prime-rate interest | This is no longer just a technical shift. The program stayed alive and became partly pre-funded, but also became longer dated and less suitable for a short-term revenue read |
This is the key caveat. The company gives unusually good detail on the two strategic threads, but it does not say what share of the NIS 76.4 million year-end manufacturing backlog comes from those two contracts. So it would be wrong to mechanically map the disclosed dollar amounts into the shekel backlog table and claim that a defined share of the backlog is already covered by those terms. What can be said is narrower and still important: the disclosed delays do not read like silent demand erosion. They read like contractual rephasing of programs that are still alive.
Advances and Interest Improve Cash Quality, Not Recognition Speed
This is the real distinction. In the second contract, Astigi is not left with only a promise of future delivery. Part of the delay is backed by customer advances, and another part earns prime-rate interest. Put differently, the customer gets more time, but not for free. For a manufacturing program, that is better backlog quality than a plain postponement where delivery slips and the supplier fully finances the delay.
But an advance is not revenue, and interest is not a substitute for operating margin. So a backlog that is better supported on the cash side can still be less attractive on recognition timing. About 56.5% of the year-end manufacturing backlog is scheduled for 2026, about 32.1% for 2027, and about 11.4% only from 2028 onward. Investors should not read the NIS 76.4 million headline as if it all belongs to the next 12 months.
That is also why this rephasing does not look like an immediate liquidity event. The company says it expects to meet its financial obligations on time, and at year-end 2025 it held about NIS 85 million of cash, cash equivalents, and marketable collateral. In other words, this is first a timing-and-conversion issue, not a survival or emergency-funding issue.
The Conversion Test Already Showed Up in the Second Half
This is where backlog quality and earnings quality must not be confused. Even if the disclosed delays are commercially reasonable and partly protected by advances and interest, the second half of 2025 already showed that manufacturing backlog does not automatically convert into smooth profitability.
Second-half 2025 development-and-manufacturing revenue rose to NIS 19.9 million, up 16% versus the comparable period. But segment operating profit fell to only NIS 0.343 million from NIS 4.1 million, and Adjusted EBITDA dropped to NIS 3.15 million from NIS 5.45 million. In margin terms, that is a fall to 15.9% from 31.9%. The company attributes the pressure to shekel strength versus the dollar, higher wage costs from employee hiring, and higher amortization of capitalized costs into cost of sales.
The gap between the two halves is especially sharp. Using the annual and second-half numbers together, the first half of 2025 implies about NIS 23.6 million of revenue, about NIS 8.4 million of operating profit, and about NIS 9.6 million of Adjusted EBITDA for the segment. That means the same backlog that gives better business visibility still has not proved a smooth and consistent path into earnings.
That is the core read. Rephasing the two strategic contracts does not destroy backlog quality. In one case it even got reinforced through a follow-on agreement, and in the other through advances and interest. But it does change the right way to read the backlog. This is less an immediate-revenue story and more a staged conversion story, with partial customer funding, inside a segment that is still very sensitive to FX and execution costs.
Conclusion
The follow-up thesis is simple: Astigi's year-end 2025 manufacturing backlog looks more contractually solid than the word "delay" suggests. Part of it is backed by advances, part of it earns interest, and one program even received an additional order. But at the same time it is also longer dated, less immediate for revenue recognition, and not enough to erase the conversion test that the second half already exposed.
So the market should not ask only whether there is backlog. That part is clear. The right question is whether the 2026 and 2027 backlog will convert into shipments, revenue, and better profitability than what the second half showed. Until that is proved, the manufacturing backlog is a real advantage, but not a blank check on near-term earnings.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.